KOSDAQBiotech & Pharma199800

ToolGen Incorporated

₩27,500▼ 0.18%2026-11-18 close
Market Cap
₩268.8B
Turnover
₩200M
Volume
6.3K
Shares out.
9.8M
PER
—
PBR
4.2×
EPS
-₩4,893
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

ToolGen: Five Straight Quarters of Losses as Patent Battles Continue

ToolGen is building its business around CRISPR patent monetization and litigation, yet operating losses and net losses attributable to controlling shareholders have persisted for five consecutive quarters through Q3 2026.

  1. 1

    Revenue reached KRW 1.31 billion in 2025, the highest of 2022 to 2025, while the operating loss widened to KRW 23.3 billion.

  2. 2

    Net income attributable to controlling shareholders swung from a KRW 6.23 billion profit in 2024 to a KRW 36.8 billion loss in 2025, and the net loss over the latest four quarters totals KRW 43.3 billion.

  3. 3

    The CRISPR patent contest is described as a three-way fight among the UC Berkeley and CVC group, the Broad Institute and ToolGen, and the interference proceeding with Broad entered its Priority phase on March 31, 2026.

  4. 4

    ToolGen decided on a rights offering of roughly KRW 70 billion, equal to about 8.6% of its outstanding shares, to fund patent disputes and R&D.

  5. 5

    The in vivo gene-editing therapy TGT-002, co-developed with GenEditBio, entered GLP toxicology testing in September 2026.

02

Business structure

ToolGen was founded in 1999 as a genome-editing company and moved to KOSDAQ in 2021 after listing on KONEX in 2014. Its business rests on three pillars: patent monetization of its CRISPR-Cas9 platform, therapeutic development using gene-editing technology, and crop and seed improvement.

Licensing income is the core of revenue. Of 2025 total revenue of KRW 1.31 billion, licensing income was KRW 1.05 billion, while cell line and animal sales were KRW 9.1 million and other items such as products and research services were KRW 186 thousand, according to the securities filing.

Revenue for the first quarter of 2026 on a cumulative basis showed cell line and animal sales rising to about KRW 104 thousand, a sign that non-licensing revenue is starting to change mix. Exports were the larger share of 2025 revenue, at about KRW 1.00 billion versus about KRW 305 thousand domestically.

In November 2026, a report said a Bioneer agreement was expanded to include next-generation high-precision gene-editing technology. On the collaboration side, ToolGen signed a cross-license agreement with GenEditBio in 2025 to jointly develop pipelines. The largest shareholder is Genexine, which held 12.45% as of May 28, 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩600M-₩5.4B−858.5%
2025Q4₩400M-₩6.9B−1716.9%
2026Q1₩400M-₩4.6B−1175.6%
2026Q2₩500M-₩6.9B−1414.5%
2026Q3₩400M-₩10B−2835.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩700M-₩19.4B-₩18.2B−2607.5%−25.8%7.0%
2023₩1.1B-₩17.1B-₩42.3B−1548.6%−140.7%210.5%
2024₩900M-₩21.8B₩6.2B−2446.6%10.7%29.2%
2025₩1.3B-₩23.3B-₩36.8B−1783.0%−65.8%10.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 743 million in 2022 to KRW 1.1 billion in 2023, a 48.4% increase, then fell to KRW 891 million in 2024, down 19.3%, before recovering to KRW 1.31 billion in 2025, up 46.6%. 2025 was the largest year of the 2022 to 2025 span.

The operating loss was KRW 19.4 billion in 2022, KRW 17.1 billion in 2023 with the loss narrowing, KRW 21.8 billion in 2024 with the loss widening, and KRW 23.3 billion in 2025 with the loss widening again. The operating margin was -2,607.5% in 2022, -1,548.6% in 2023, -2,446.6% in 2024 and -1,783.0% in 2025.

The 2025 margin improved on 2024 because revenue growth of 46.6% outpaced the 6.9% growth in the operating loss. A securities data provider's 2025 annual commentary attributes the wider operating loss to higher R&D spending despite revenue growth.

Net loss attributable to controlling shareholders was KRW 18.2 billion in 2022 and KRW 42.3 billion in 2023, swung to a KRW 6.23 billion profit in 2024, and returned to a KRW 36.8 billion loss in 2025. Net income including non-controlling interests moved in the same direction and matched these figures in each year.

Operating cash flow was -KRW 15 billion in 2022, -KRW 14.9 billion in 2023, -KRW 16.5 billion in 2024 and -KRW 20.2 billion in 2025.

At the end of 2025, total equity was KRW 55.9 billion, all attributable to controlling shareholders, and total liabilities were KRW 5.8 billion, with the debt ratio falling from 210.5% in 2023 to 29.2% in 2024 and 10.4% in 2025.

Quarterly revenue went from KRW 631 million in Q3 2025 to KRW 404 million in Q4 2025, a 35.9% quarter-on-quarter decline, then KRW 391 million in Q1 2026, KRW 487 million in Q2 2026 and KRW 352 million in Q3 2026, which was down 44.2% year on year.

Operating loss widened from KRW 5.41 billion in Q3 2025 to KRW 9.97 billion in Q3 2026, so falling revenue and a larger loss appeared together.

Net loss attributable to controlling shareholders went from KRW 22.5 billion in Q4 2025 to KRW 4.41 billion in Q1 2026, then KRW 6.79 billion in Q2 2026 and KRW 9.61 billion in Q3 2026. The net loss attributable to controlling shareholders over the latest four quarters totals KRW 43.3 billion.

05

Industry analysis

Market research firm Mordor Intelligence estimates that the gene-editing therapeutics market will grow from USD 4.53 billion in 2025 to USD 11.23 billion by 2030. Reports indicate that RNP technology is applied in the only gene-editing therapy approved by the U.S. FDA.

The patent landscape is a three-way contest among the UC Berkeley and CVC group, the Broad Institute and ToolGen. In a remanded interference proceeding on CRISPR-Cas9 for human cells, the PTAB recognized Broad's priority.

That result could be read as unfavorable to ToolGen, yet ToolGen's shares rose about 20% on the day. Analysts said that clearer patent ownership made royalty structures easier to gauge.

ToolGen sued Vertex Pharmaceuticals in the United States and filed an infringement suit against Lonza in a Dutch court, which handles production for the Casgevy therapy. The company has said it holds the only registered Korean CRISPR-Cas9 foundational patent.

In crops, the securities filing describes seed development on EPSPS-edited lines and maize transformation systems now being built in-house. Because licensing drives most revenue, results and share price tend to react to patent rulings and contract signings more than to clinical milestones.

06

Outlook

ToolGen decided in May 2026 on a rights offering of roughly KRW 70 billion and said the proceeds will fund its response to the interference proceeding with the Broad Institute, litigation costs against Vertex and Lonza, next-generation pipeline R&D and global operations.

On litigation, the company said its suit against Vertex had a changed schedule and that three newly registered CRISPR RNP patents were added as targets of infringement. The interference proceeding with Broad formally began its Priority phase as of March 31, 2026.

In the pipeline, TGT-002, a co-development with GenEditBio, moved into GLP toxicology, and reports say the company plans a U.S. clinical application next year.

In mid-November 2026, ToolGen announced a Korean patent grant for low-immunogenicity stem cells, which it presented as a basis for allogeneic cell therapies and bioengineered organs. The Bioneer agreement fits a stated plan to use the research market as a launch pad for therapeutic patent licensing.

The CEO framed 2026 as the year technology value should translate into financial results. The next checkpoints are the annual revenue mix and operating loss trend in the 2026 annual report, and the progress of the Priority phase and the Vertex litigation.

07

Valuation

PER
—
PBR
4.2×
ROE
-78.9%
EPS
-₩4,893
BPS
₩6,492
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the last four quarters show net losses. The price-to-book ratio sits well above total equity of KRW 55.9 billion at the end of 2025, which means a large premium over net asset value.

The company has no confirmed shareholder return through dividends, so dividend-based valuation has limited application. Because earnings-based multiples are of little use here, the market value appears to rest more heavily on expected patent royalties and pipeline value.

Over several years, net income attributable to controlling shareholders moved from a 2024 profit to a 2025 loss, and the operating loss grew from KRW 19.4 billion in 2022 to KRW 23.3 billion in 2025.

The rights offering increased the share count and diluted existing holders, a factor to weigh in any per-share comparison.

Within biotech, companies whose income comes mainly from licensing and companies whose value depends on clinical results use different valuation anchors, so peer comparisons should account for that difference.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Wider patent coverage

A U.S. patent covering direct delivery of Cas9 and gRNA complexes into cells was granted in November 2025, and a European RNP patent cleared its grant notice in December 2025. Three newly registered RNP patents were added as infringement targets in the Vertex litigation in 2026. ToolGen plans to extend these claims to other RNP-dependent applications.

Possible RNP royalty layer

If RNP delivery becomes an essential step in therapeutic development, an additional royalty layer separate from the foundational patents could emerge. Global drugmakers using RNP would then need separate licenses from patent holders, and the technology is reported to be used in the approved Casgevy therapy.

Balance sheet and pipeline progress

Total equity at the end of 2025 was KRW 55.9 billion against total liabilities of KRW 5.8 billion, a light debt load. TGT-002 is a co-developed in vivo gene-editing therapy that has entered GLP toxicology, and the cross-license gives access to GenEditBio's LNP technology. The shared development structure spreads some pipeline risk.

09

Bear factors

Five quarters of losses and falling sales

Operating losses and net losses attributable to controlling shareholders have persisted for five consecutive quarters through Q3 2026. Q3 2026 revenue fell 44.2% year on year to KRW 352 million, while the operating loss widened to KRW 9.97 billion.

The net loss attributable to controlling shareholders over the latest four quarters totals KRW 43.3 billion, and non-licensing revenue has not grown enough to offset it.

Dilution and funding needs

The offering equals about 8.6% of outstanding shares, according to the company, and Genexine plans to take part of its allotment. Much of the proceeds is earmarked for patent disputes and interference proceedings, so funding pressure may persist until business income offsets losses. Operating cash flow was -KRW 20.2 billion in 2025.

Uncertainty in patent rulings

The PTAB ruling was read by some as unfavorable to ToolGen. Reports from late 2025 also noted Vertex's argument that the European claims lacked inventive step. The Vertex litigation schedule has also been changed. Shifting rulings and dates make the timing and size of licensing income harder to predict.

10

Risk factors

Patent and litigation outcomes

If the interference with the Broad Institute does not confirm priority, the scope of ToolGen's CRISPR-Cas9 foundational patents could be limited. Litigation costs in the United States and Europe against Vertex and Lonza keep accruing. An unfavorable ruling could weaken both licensing income and royalty expectations at the same time.

Funding and dilution

The roughly KRW 70 billion rights offering, equal to about 8.6% of shares, dilutes existing holders. If litigation and R&D spending continue, further financing may be required. With operating cash flow at -KRW 20.2 billion in 2025, the funding need is not small.

Clinical and commercial delays

TGT-002 is still in GLP toxicology and has not entered the clinic, with a U.S. clinical filing planned for next year. Because revenue leans on licensing and patent income, any delay in the therapeutic program would slow revenue diversification. The timing of commercialization for the seed business has not been disclosed.

11

What to watch next

  1. Late March 2027

    Submission of the 2026 annual report, the first audited filing that confirms Q4 and full-year 2026 revenue and operating loss.

  2. Mid-May 2027

    Q1 2027 quarterly report, where the trend of quarterly revenue relative to the 2026 range and the operating loss trajectory can be checked.

  3. During 2027 (date not disclosed)

    Whether and when the U.S. clinical application for TGT-002 is filed, the first indicator of whether the therapeutic pipeline can complement licensing-led revenue.

  4. Date not disclosed (formal Priority phase opened March 31, 2026)

    The outcome of the Priority phase with the Broad Institute and the progress of the Vertex litigation after its schedule change, a turning point for royalty scope and licensing income.

12

Overall view

Since its founding in 1999, ToolGen has relied on licensing income tied to its CRISPR foundational patents, and 2025 revenue of KRW 1.31 billion was the highest of 2022 to 2025.

Even so, the operating loss reached KRW 23.3 billion and the net loss attributable to controlling shareholders reached KRW 36.8 billion in 2025, and five consecutive quarters of losses have followed through Q3 2026.

On patents, the Priority phase of the interference with the Broad Institute formally opened after the March 2026 PTAB decision, alongside the litigation against Vertex and Lonza and newly registered RNP patents.

On financing, a rights offering of roughly KRW 70 billion decided in May 2026 is intended for litigation and R&D and carries about 8.6% dilution. In the pipeline, TGT-002 has entered GLP toxicology with a U.S. clinical filing planned for next year.

Bullish factors include wider patent coverage, a possible RNP royalty layer and a balance sheet with KRW 55.9 billion of equity. Bearish factors include five straight quarters of losses, falling sales, further funding needs and uncertain rulings.

The next checkpoints are the revenue mix and operating loss trend in the 2026 annual report, the Q1 2027 quarterly report and the outcome of the Priority phase.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. jobkorea.co.kr
  3. toolgen.com
  4. v.daum.net
  5. kind.krx.co.kr
  6. view.asiae.co.kr
  7. investing.com
  8. v.daum.net
  9. hankyung.com
  10. saramin.co.kr
  11. news.nate.com
  12. v.daum.net
  13. pharmnews.com
  14. m.medigatenews.com
  15. news1.kr
  16. etoday.co.kr
  17. edaily.co.kr
  18. etoday.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis